{
  "schema_version": 1,
  "generated_at": "2026-05-20T10:39:12Z",
  "ticker": "BEAM",
  "headlines": [
    {
      "title": "Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?",
      "publisher": "Zacks",
      "published_at": "2026-05-19T15:53:00+00:00",
      "age_hours": 18.77004869944444,
      "link": "https://finance.yahoo.com/sectors/healthcare/articles/intellias-pipeline-push-drive-long-155300020.html",
      "summary": "NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth."
    },
    {
      "title": "Beam Therapeutics Data Puts BEAM 302 And AAT Disease In Focus",
      "publisher": "Simply Wall St.",
      "published_at": "2026-05-19T08:11:32+00:00",
      "age_hours": 26.4611598125,
      "link": "https://finance.yahoo.com/sectors/healthcare/articles/beam-therapeutics-data-puts-beam-081132363.html",
      "summary": "Beam Therapeutics (NasdaqGS:BEAM) reported positive Phase 1/2 data for its BEAM-302 program at a major international conference. The gene editing therapy showed durable restoration of alpha-1 antitrypsin function, targeting both lung and liver manifestations of the disease. Beam plans to expand the BEAM-302 trial and work with the FDA on a potential accelerated approval pathway. For investors watching genetic medicine, this update puts Beam Therapeutics back in focus. The stock last closed..."
    },
    {
      "title": "Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?",
      "publisher": "Motley Fool",
      "published_at": "2026-05-18T18:25:44+00:00",
      "age_hours": 40.22449314694444,
      "link": "https://www.fool.com/coverage/filings/2026/05/18/hedge-fund-drops-usd40-million-on-gene-editing-biotech-beam-is-it-a-buy/",
      "summary": "Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases."
    },
    {
      "title": "Earnings Update: Beam Therapeutics Inc. (NASDAQ:BEAM) Just Reported And Analysts Are Boosting Their Estimates",
      "publisher": "Simply Wall St.",
      "published_at": "2026-05-11T15:24:47+00:00",
      "age_hours": 211.2403264811111,
      "link": "https://finance.yahoo.com/markets/stocks/articles/earnings-beam-therapeutics-inc-nasdaq-152447897.html",
      "summary": "A week ago, Beam Therapeutics Inc. ( NASDAQ:BEAM ) came out with a strong set of quarterly numbers that could..."
    },
    {
      "title": "BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates",
      "publisher": "Zacks",
      "published_at": "2026-05-08T16:07:00+00:00",
      "age_hours": 282.53671537111114,
      "link": "https://finance.yahoo.com/sectors/healthcare/articles/beams-q1-loss-wider-expected-160700976.html",
      "summary": "Beam Therapeutics Q1 revenues beat estimates as its gene-editing pipeline advanced, with key updates across the SCD, AATD and PKU programs."
    }
  ]
}